MedTrace Logo

18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer.

NCT00414934 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2009-08-17

No results posted yet for this study

Summary

18F ion is a positron emitting bone radiopharmaceuticals. The skeletal uptake of 18F relies on the exchange of hydroxyl ions in the hydroxyapatit crystal which is an indicator of bone metabolic activity (8). It has good soft tissue clearance and high affinity of to the bone matrix. It is able to perform a highly sensitive whole-body screening for bone metastases using a high resolution PET scanner. Therefore, we conduct a prospective study to evaluate the accuracy and clinical value of 18F PET in staging bone metastases by

1. Comparing the sensitivity of 18F-NaF PET with that of 99mTc-MDP scintigraphy;
2. Determining the clinical impact of PET results on subsequent patient management.

Conditions

Sponsors & Collaborators

  • Far Eastern Memorial Hospital

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ruoh-Fang Yen, M.D.,Ph.D. · National Taiwan University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00414934 on ClinicalTrials.gov